Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Brolizum is indicated for:
Pharmacology
When PD-L1 and PD-L2 (the ligands of PD-1) bind to the PD-1 receptor on T cells, T cell proliferation and cytokine production are inhibited. Some tumors produce more of these ligands, and signaling through this pathway can help block the T-cell immune surveillance that would normally be watching for tumor cells.
Pembrolizumab is a monoclonal antibody. It binds to the PD-1 receptor and stops it interacting with PD-L1 and PD-L2. This releases the PD-1 pathway-mediated inhibition of the immune response, and that includes the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity led to decreased tumor growth.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
For melanoma, NSCLC, SCLC and HNSCC, the Pembrolizumab dose is 200 mg every 3 weeks. In cHL or PMBCL, adults also get 200 mg every 3 weeks, while children get 2 mg/kg (up to 200 mg) every 3 weeks. Urothelial carcinoma is again 200 mg every 3 weeks.
For MSI-H cancer, adults get 200 mg every 3 weeks and children get 2 mg/kg (up to 200 mg) every 3 weeks. Gastric cancer, esophageal cancer, cervical cancer and HCC are each treated with 200 mg every 3 weeks. MCC follows the same pattern as cHL and PMBCL: 200 mg every 3 weeks for adults, and 2 mg/kg (up to 200 mg) every 3 weeks for children.
In RCC, Pembrolizumab 200 mg every 3 weeks is given together with axitinib 5 mg orally twice daily. In endometrial carcinoma, the dose is 200 mg every 3 weeks together with lenvatinib 20 mg orally once daily, for tumors that are not MSI-H or dMMR.
Pembrolizumab is given as an intravenous infusion over 30 minutes.
Side Effects
The most common side effects, reported in 20% or more of patients (≥20%), depend on how Pembrolizumab is given. When Pembrolizumab is used alone, the reactions are fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain. Given together with chemotherapy, the common ones are fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, and stomatitis. Combined with axitinib, patients reported diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation. For Pembrolizumab combined with lenvatinib, the list is fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar erythrodysesthesia, dyspnea, cough, and rash.
Pregnancy & Breastfeeding
Pembrolizumab can harm an unborn baby when it is given to a pregnant woman. This is based on how the medicine works. There are no human data on the risk of toxicity to the embryo or fetus.
It is also not known whether pembrolizumab passes into animal or human milk, or what effect it might have on a breastfed child or on milk production. Because breastfed children could have serious adverse reactions, women are advised not to breastfeed while being treated with Pembrolizumab, and for 4 months after the final dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Pembrolizumab has not been shown to be safe or effective in children, so its use in pediatric patients is not established. In elderly patients, no overall differences in safety or effectiveness were seen when compared with younger patients.
Storage
Keep Pembrolizumab vials in a refrigerator, at 2°C to 8°C.
Common questions about Brolizum 100 mg/4 ml
What is Brolizum 100 mg/4 ml IV Infusion?
Brolizum 100 mg/4 ml IV Infusion is a medicine that contains Pembrolizumab. It is made by Incepta Pharmaceuticals Ltd. It belongs to the Immunological Chemotherapy group of medicines.
What is Brolizum used for?
Brolizum is used for: Cancer.
What are the side effects of Brolizum?
The most common side effects, reported in 20% or more of patients (≥20%), depend on how Pembrolizumab is given. When Pembrolizumab is used alone, the reactions are fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.
Can I take Brolizum during pregnancy or while breastfeeding?
Pembrolizumab can harm an unborn baby when it is given to a pregnant woman. This is based on how the medicine works. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Brolizum?
Keep Pembrolizumab vials in a refrigerator, at 2°C to 8°C.
Do I need a prescription for Brolizum?
Brolizum is a prescription (Rx) medicine. Take it as your doctor advises.